Logo image of CNTX

CONTEXT THERAPEUTICS INC (CNTX) Stock Fundamental Analysis

NASDAQ:CNTX - Nasdaq - US21077P1084 - Common Stock - Currency: USD

0.8431  -0.02 (-2.54%)

After market: 0.8431 0 (0%)

Fundamental Rating

3

CNTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 197 industry peers in the Pharmaceuticals industry. While CNTX has a great health rating, there are worries on its profitability. CNTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CNTX had negative earnings in the past year.
In the past year CNTX has reported a negative cash flow from operations.
CNTX had negative earnings in 4 of the past 5 years.
CNTX had a negative operating cash flow in each of the past 5 years.
CNTX Yearly Net Income VS EBIT VS OCF VS FCFCNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -27.24%, CNTX is in line with its industry, outperforming 56.57% of the companies in the same industry.
With a decent Return On Equity value of -28.05%, CNTX is doing good in the industry, outperforming 64.65% of the companies in the same industry.
Industry RankSector Rank
ROA -27.24%
ROE -28.05%
ROIC N/A
ROA(3y)-71.84%
ROA(5y)235.37%
ROE(3y)-90.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNTX Yearly ROA, ROE, ROICCNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

CNTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTX Yearly Profit, Operating, Gross MarginsCNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, CNTX has more shares outstanding
The number of shares outstanding for CNTX has been increased compared to 5 years ago.
There is no outstanding debt for CNTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CNTX Yearly Shares OutstandingCNTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CNTX Yearly Total Debt VS Total AssetsCNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

CNTX has an Altman-Z score of 14.67. This indicates that CNTX is financially healthy and has little risk of bankruptcy at the moment.
CNTX has a Altman-Z score of 14.67. This is amongst the best in the industry. CNTX outperforms 91.92% of its industry peers.
CNTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.67
ROIC/WACCN/A
WACCN/A
CNTX Yearly LT Debt VS Equity VS FCFCNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 35.62 indicates that CNTX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 35.62, CNTX belongs to the best of the industry, outperforming 99.49% of the companies in the same industry.
CNTX has a Quick Ratio of 35.62. This indicates that CNTX is financially healthy and has no problem in meeting its short term obligations.
CNTX has a better Quick ratio (35.62) than 99.49% of its industry peers.
Industry RankSector Rank
Current Ratio 35.62
Quick Ratio 35.62
CNTX Yearly Current Assets VS Current LiabilitesCNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 64.67% over the past year.
EPS 1Y (TTM)64.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CNTX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.21% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y47.96%
EPS Next 2Y15.75%
EPS Next 3Y-1.91%
EPS Next 5Y0.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNTX Yearly Revenue VS EstimatesCNTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
CNTX Yearly EPS VS EstimatesCNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CNTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CNTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTX Price Earnings VS Forward Price EarningsCNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTX Per share dataCNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.75%
EPS Next 3Y-1.91%

More info and screens

0

5. Dividend

5.1 Amount

CNTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONTEXT THERAPEUTICS INC

NASDAQ:CNTX (4/17/2025, 8:10:28 PM)

After market: 0.8431 0 (0%)

0.8431

-0.02 (-2.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-20 2025-03-20/amc
Earnings (Next)05-07 2025-05-07
Inst Owners97.4%
Inst Owner ChangeN/A
Ins Owners1.45%
Ins Owner Change0%
Market Cap75.63M
Analysts81.82
Price Target6.38 (656.73%)
Short Float %3.34%
Short Ratio12.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-23.84%
Min EPS beat(2)-105.41%
Max EPS beat(2)57.74%
EPS beat(4)3
Avg EPS beat(4)12.2%
Min EPS beat(4)-105.41%
Max EPS beat(4)57.74%
EPS beat(8)3
Avg EPS beat(8)-18.03%
EPS beat(12)7
Avg EPS beat(12)-8.28%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.76%
PT rev (3m)-15.25%
EPS NQ rev (1m)50.21%
EPS NQ rev (3m)0.42%
EPS NY rev (1m)38.26%
EPS NY rev (3m)18.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 0.79
EV/EBITDA N/A
EPS(TTM)-0.53
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS1.06
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.24%
ROE -28.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.84%
ROA(5y)235.37%
ROE(3y)-90.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 66.97%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 35.62
Quick Ratio 35.62
Altman-Z 14.67
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)155.66%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.48%
EPS Next Y47.96%
EPS Next 2Y15.75%
EPS Next 3Y-1.91%
EPS Next 5Y0.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.84%
OCF growth 3YN/A
OCF growth 5YN/A